Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
March 28, 2024 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis
October 05, 2022 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments
May 12, 2022 08:00 ET
|
Monopar Therapeutics Inc.
Validive® Phase 2b/3 VOICE Trial Continues Enrolling Patients Toward InterimCamsirubicin Phase 1b Dose-Escalation Trial Clears 3rd Dose Level, Now Enrolling 4th WILMETTE, Ill., May 12, 2022 (GLOBE...